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Abstract.  The role of latent transforming growth 
factor-/~  (TGF-/3) binding protein (LTBP) in the associ- 
ation of TGF-~ 1 to the extracellular matrix of cultured 
fibroblasts and HT-1080 fibrosarcoma cells was studied 
by immunochemical methods.  The matrices were iso- 
lated from the cells, and the levels of LTBP and TGF- 
/~1  were estimated by immunoblotting and immunopre- 
cipitation.  LTBP,  TGF-/31,  and its propeptide (latency- 
associated peptide, LAP) were found to associate to 
the extracellular matrix.  Immunoblotting analysis indi- 
cated that treatment of the cells with plasmin resulted 
in a concomitant time and dose dependent release of 
both LTBP and TGF-~I  from the extracellular matrix 
to the supernatant.  Comparison of molecular weights 
suggested that plasmin treatment resulted in the cleav- 
age of LTBP from the high molecular weight fibroblast 
form to a form resembling the low molecular weight 
LTBP found in platelets.  Pulse-chase and immunopre- 
cipitation analysis indicated that both the free form of 
LTBP and LTBP complexed to latent TGF-/$ were 
efficiently incorporated in the extracellular matrix, 
from where both complexes were slowly released to 
the culture medium.  Addition of plasmin to the chase 
solution resulted, however, in a  rapid release of LTBP 
from the matrix.  Fibroblast derived LTBP was found 
to associate to the matrix of HT-1080 cells in a plas- 
min sensitive manner as shown by immunoprecipita- 
tion analysis.  These results suggest that the latent form 
of TGF-/31 associates with the extracellular matrix via 
LTBP,  and that the release of latent TGF-/~ 1 from the 
matrix is a consequence of proteolytic cleavage(s) of 
LTBP. 
I~OWTH factors of the TGF-/~ family have diverse ef- 
fects on cell growth,  morphology,  and differentia- 
tion. TGF-ffs also have an important role in control- 
ling the proteolytic balance of cells and the production and 
structure of the extracellular  matrix (for review  see Lyons 
and Moses,  1990; Massagu6,  1990;  Laiho and Keski-Oja, 
1992; Miyazono et al., 1993). Three isoforms of TGF-/~ have 
been found in mammals, TGF-ffs 1, 2, and 3 (Derynck et al., 
1985, 1988; de Martin et al.,  1987; ten Dijke et al.,  1988). 
After synthesis,  two chains of pro-TGF-/3 associate to form 
a  disulfide  bonded dimer.  Homodimeric  forms are  most 
common,  but the  heterodimers  TGF-/~I.2  and  TGF-/$2.3 
have also been isolated (Cheifetz et al., 1987; Ogawa et al., 
1992). TGF-ffs are secreted by cultured cells as latent com- 
plexes.  During  secretion the carboxy-terminal  chains  con- 
stituting  mature  TGF-/~ are  cleaved  from  their  amino- 
terminal propeptides. The disulfide linked propeptide dimer 
(TGF-/~I  latency  associated  protein,  LAP  1)  renders  the 
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1. Abbreviations  used in this paper: LAP, latency-associated protein; LTBP, 
latent TGF-/3 binding protein. 
secreted TGF-/3 latent by remaining noncovalently associated 
to dimeric  TGF-/L 
A fraction of latent TGF-/~ contains additional high molecu- 
lar weight proteins,  which are associated with LAP (Miya- 
zono et al.,  1988; Wakefield et al.,  1988; Olofsson  et al., 
1992). Best characterized  of these is latent TGF-/$ binding 
protein (LTBP), which is bound to LAP by a disulfide bond 
(Miyazono et al., 1988). The amino acid sequence of LTBP 
is highly repetitive, containing  16 EGF-like repeats and three 
novel "LTBP-Iike" repeats (Kanzaki et al., 1990; Tsuji et al., 
1990). LTBP-Iike repeat structures are also present in fibril- 
lin (Maslen et al.,  1991), a proteinase sensitive component 
of the elastic fibers, suggesting that LTBP is a component of 
the extracellular  matrix.  Fibroblasts produce high molecular 
mass (190 kD) form of LTBP, while the form of LTBP con- 
tained in the platelet a-granules (Assoian and Sporn, 1986; 
Fava et al., 1990) is smaller,  125-160 kD, due to proteolytic 
processing (Kanzaki et al., 1990; Tsuji et al., 1990). The ex- 
pression of LTBP is often co-regulated with TGF-/~I (Miya- 
zono et al., 1991; Taipale, J., S. Matikainen,  M. Hurme, and 
J. Keski-Oja,  manuscript submitted  for publication). 
TGF-/3 has a major role in the regulation  of extracellular 
matrix synthesis and degradation.  TGF-/~ stimulates the syn- 
thesis of multiple  extracellular  matrix components,  includ- 
ing  collagens,  fibronectin,  vitronectin,  tenascin,  and pro- 
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1991; Pearson et al.,  1988; Bassols and Massagu6,  1988). 
It also suppresses matrix degradation  by downregulating the 
expression of proteinases,  such  as plasminogen  activators 
(Laiho et al., 1986), collagenase (Edwards et al., 1987), and 
stromelysin (Kerr et al.,  1990), and by inducing proteinase 
inhibitors,  such as plasminogen  activator inhibitor-I  (PAI-1; 
Laiho et al.,  1986, 1987) and tissue inhibitor  of metallo- 
proteinase-1  (TIMP-1; Edwards  et al.,  1987). Interestingly, 
TGF-~I itself is a component of the extracellular  matrix, and 
can be released by proteinases (Taipale et al.,  1992).  Fur- 
thermore,  the  presence  of extracellular  matrix  has  been 
found to downregulate  the expression  of the TGF-/31 gene 
(Streuli  et al.,  1993).  TGF-~I  may thus act as a feedback 
regulator of extracellular  matrix formation. 
Latent forms of  TGF-~ can be activated by extremes of pH, 
heat treatment,  certain glycosidases and by the protease plas- 
min (Lawrence et al.,  1985; Brown et al., 1990; Miyazono 
et al.,  1988; Lyons et al.,  1988). Latent TGF-/3 is also acti- 
vated in co-cultures of endothelial  cells and smooth muscle 
cells by plasmin-mediated  proteolysis  (Antonelli-Olridge  et 
al.,  1989; Sate and Rifkin,  1989).  Studies using these co- 
culture models also suggest  that  transglutaminase,  an en- 
zyme involved in the cross-linking  of extracellular  matrix 
proteins, and latent TGF-/~ binding protein, are required for 
the activation  of latent  TGF-/3 (Kojima et al.,  1993; Flau- 
menhaft et al.,  1993). 
We have found earlier that TGF-/~I is associated with the 
extraceUular  matrix  of human fibroblasts  and fibrosarcoma 
cells, and that it can be released from the extraceUular matrix 
in a latent  form by plasmin  and thrombin  (Taipale et al., 
1992). The release of latent TGF-/31 from the matrix of en- 
dothelial  cells by plasmin  (Falcone  et al.,  1993)  and  by 
thrombin (Benezra  et al.,  1993) have also been observed. 
The structure of the matrix form as well as the molecular ba- 
sis of latency of the TGF-~ released by proteinases have not 
been understood. This study was carried out to analyze the 
association of LTBP with the extracellular  matrix and its role 
in the proteolytic release of latent  TGF-/~I. 
Materials and Methods 
Reagents 
Plasmin (specific activity 21.3 CU/mg protein) was purchased from Kabi 
(M61ndal,  Sweden).  [35S]cysteine  (specific activity  1300  Ci/mmol) was 
from Amersham (Buckinghamshire, England). Bolton-Hunter labeled 1251- 
TGF-~I (specific activity 158 #Ci/#g) used as a standard was from Du Pont 
(NEN Research Products, Wilmington, DE).  Human LTBP was purified 
from outdated platelets according to Miyazono et al. (1988).  Recombinant 
small latent TGF-/31 was purified according to Miyazono et al. (1991) from 
Chinese hamster ovary cells transfected with TGF-~I cDNA (gift from Dr. 
Hideya Ohashi, Kirin Brewery Co., Ltd., Gumma, Japan). All other re- 
agents were from commercial sources and of the highest purity available. 
Cell Culture 
Human  fibrosarcoma HT-1080  cells (CCL-121;  American Type Culture 
Collection, Rockville, MD) and human embryonic lung fibroblasts (CCL- 
137;  ATCC)  were  grown  in  Eagle's  modification of minimal  essential 
medium (MEM) containing 10% FCS, 100 IU/ml penicillin and 50 #g/ml 
streptomycin. All experiments were carded out under serum-free condi- 
tions. Before commencing experiments, the cells were washed twice with 
serum free medium and incubated in serum free medium for 1-6 h to re- 
move traces of serum proteins. Essentially similar results were obtained 
using fibroblasts and HT-1080 cells in all experiments. HT-1080 cells were 
used in immunoprecipitation experiments due to lower background levels. 
Antibodies 
Affinity-purified peptide antibody No. 627 to TGF-B1 amino acids 78-109 
was used in immunoblotting analyses of TGF-B1 (Taipale et al., 1992). This 
antibody is functional in immunoblotting, but does not immunoprecipitate 
TGF-~I or neutralize TGF-~I activity in biological assays. Antibody LT-2 
was  raised  using purified recombinant small  latent  TGF-~I  as  antigen 
(Miyazono et al., 1991). This antibody recognizes TGF-/31 propeptide (B1- 
LAP) in immunoprecipitation. IgG fraction was purified from LT-2 serum 
by protein A-Sepharose (Pharmacia, Uppsala, Sweden) affinity chromatog- 
raphy according to manufacturer's instructions. Antibody Ab-39 (Miyazono 
et al.,  1988,  1991) was raised against purified human platelet LTBP (free 
form, devoid of LAP and TGF-B).  This antibody is functional in immune- 
blotting and immunoprecipitation of LTBP under nonreducing conditions, 
but does not react with reduced LTBP. All antibodies used were polyclonal 
rabbit antibodies. 
Extracellular Matrix Preparations 
Extracellular matrices were prepared according to Hedman et al. (1979). 
Briefly, cell cultures were washed once with PBS (0.14 M NaCl in 10 mM 
sodium phosphate buffer,  pH 7.4) and then treated three times with 0.5% 
sodium deoxycholate in 10 mM Tris-HCl buffer, pH 8.0, at 0°C for 10 min. 
The plates were then washed again with PBS and allowed to dry overnight 
at room temperature. The residue was collected to nonreducing SDS-PAGE 
sample buffer (2 % SDS) by rubber policeman and treated at 95°C for 5 rain. 
These preparations are thus sodium deoxycholate insoluble, SDS soluble 
cell extracts, referred as "matrix" in the text. In some preparations, LTBP 
cross-linked to the matrix was unmasked and made soluble by digesting the 
sodium deoxycholate insoluble residues by plasmin (0.3 CU/ml) in matrix 
digestion buffer (PBS  containing  1 mM  Ca  2+,  1 mM Mg  2+,  and 0.1% 
n-octyl-d-fl-glucopyranoside) at 370C  for 1 h. These preparations are re- 
ferred to as "matrix digest" in the text, and they contain also proteins derived 
from the highly cress-linked SDS-insoluble extracellular matrix. 
Immunoprecipitation analyses of the matrix were carded out after plas- 
min digestion. The  supernatants of plasmin digested matrices were in- 
cubated with the antibodies (see below) after inhibition of plasmin by 
phenylmethylsulfonyl fluoride (PMSE 1 raM), leupeptin (100 #g/ml), and 
aprotinin (200 IU/ml). For immunoblotting of the digested matrices, SDS 
was added (1% final concentration) without removing the plasmin solution, 
and the plates were scraped with a rubber policeman. The plasmin digested 
matrix samples (matrix plus supernatant) were then transferred to micro- 
centrifuge tubes and treated at 95°C for 5 rain before SDS-PAGE. 
SDS-insoluble extracelfular matrix proteins were prepared from the con- 
ventional matrices by treatment in 1% SDS at 95°C for 5 rain, followed by 
centrifugation at 100,000 g for 1 h. The pellets were then washed once with 
PBS to remove excess of SDS. To release associated LTBP, the pellets were 
treated with plasmin (0.3 CU/ml) in matrix digestion buffer at 37°C for I h. 
Metabolic Labeling Studies 
ExtraceUular Matrix. For metabolic labeling of the extracellular matrix, 
HT-1080 cells were seeded to new plates and cultured for 3 d in the presence 
of [35S]cysteine (50 #Ci/ml) in MEM containing 5 % FCS and 10% of the 
usual amount of cysteine (MEM contains 200 #M cysteine). The cells were 
washed three times and incubated for 24 h in serum-free MEM (no radioac- 
tive Cys). The cells were then washed three times to remove soluble radio- 
activity. This method produced extracellular matrixes of low specific radio- 
activity, but ensured that all cysteine containing proteins of the extracellular 
matrix were labeled, irrespective of turnover rate. 
Conditioned Medium.  For production of [35S]cysteineqabeled condi- 
tioned medium, confluent cultures of human fibroblasts were incubated un- 
der serum free conditions for 16 h. The cells were subsequently labeled with 
[35Slcysteine (200 #Ci/ml) in MEM containing 1% of the usual amount of 
methionine and cysteine for 16 h.  Nonmetabolic labeling of proteins by 
disulfide exchange with  [35S]cysteine  was minimized by dilution of the 
medium to MEM containing cysteine (1:1) directly after collection. 
Pulse-Chase. For pulse-chase studies, HT-1080 cells were changed to 
serum free conditions, starved for 30 min in methionine- and cysteine-free 
MEM, followed by metabolic labeling with [3~S]cysteine in cysteine-free 
MEM containing 1% of the normal amount of methionine as indicated in 
each experiment. The medium was then collected and the cells were lysed 
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8.0, at 0°C. Extracellular  matrices were prepared as described above. 
Immunoprecipitation Analyses 
For immunoprecipitation,  cell lysate, culture  medium,  and matrix  digestion 
samples were preabsorbed  by incubation  with preimmune  serum (1:500 di- 
lution) or control hyperimmune  rabbit IgG (5/~g/ml) at 0°C for 10 h fol- 
lowed by the addition  of protein A-Sepharose  beads. After mild shaking  at 
4°C for 2 h, the beads were collected by centrifugation  at 13,000 rpm for 
10 rnin in a microcentrifuge.  The supernatants  were transferred to fresh 
tubes and the preabsorption  procedure was repeated. Subsequently,  the 
samples were incubated  with the specific  antiserum  (Ab-39, 1:500  dilution) 
or purified  IgG (LT-2,  2 #g/ml)  in fresh tubes  for 2 h, followed  by incubation 
with protein A-Sepharose in an end-over  rotary shaker for 1 h. The beads 
were collected by slow centrifugation  (2,000 rpm in a microcentrifuge  for 
5 min). The beads were then washed twice with PBS, twice with detergent 
buffer (1% sodium  deoxycholate, 1% TX-100, 150 mM NaCI  in 50 mM Tris- 
HCI buffer, pH Z0), once with high salt buffer (500 mM NaCI, 0.2% TX- 
100 in 20 mM Tris-HCl  buffer, pH 7.0) followed  by three washes with PBS. 
During  the last wash the beads were transferred  to fresh tubes to avoid  con- 
tamination by plastic-binding  material. Bound material was then eluted 
from the beads  by treating  at 950C for 5 rain in gel sample  buffer  containing 
2 % SDS. Where indicated, the antibodies  were incubated  with respective 
antigens  prior to immunoprecipitation  (I tLg of antigen  incubated  with 30 t~l 
of serum or 30 #g IgG at room temperature for 15 min). 
PAGE and Immunoblotting 
Gradient (4-15%) SDS-PAGE  analysis  was carried out using the Laemmli 
(1970) buffer system. The gels were transferred to nitrocellulose  mem- 
branes (Schleicher  & Schuell,  Dassel, Germany)  and the filters  were treated 
at 80°C under vacuum for 1 h to fix the transferred proteins. 
For sodium deoxycholate-PAGE, samples were cooled to 0°C and an 
equal volume  of sample  loading  buffer  (200 mM Tris-HCl,  pH 8.0, contain- 
ing 10 %  glycerol  and 1% sodium  deoxycholate) was added at 0°C. The sam- 
pies were then electrophoresed on pre-cast  4-15  % polyacrylamide  rninigels 
not containing  SDS (Bio Rad Laboratories, Hercules, CA) on a minigel  ap- 
paratus (Mini  protean  II; Bio Rad Laboratories). Electrophoresis  buffer  was 
50 mM Tris/192  mM glycine  (pH '~8.3) containing  0.1% sodium  deoxycho- 
late. The electrophoresis was carried out at 0*C (20 mA constant  current) 
until the phenol red marker dye exited the gel. Proteins from sodium 
dooxycholate-PAGE  gels were electrophoretically  transferred  to Immobilon 
P (Millipore Corp., Richmond, CA) membranes according to rnanufac- 
turer's instructions  (Millipore  Corp., and Bio Rad Laboratories). Transfer 
was carried out in a 30 mM Tris/200  mM glycine  buffer  (pH '~8.3) contain- 
ing 0.01% SDS and 10% methanol.  Extensive  characterization  of the elec- 
trophoretic properties of this system  was not done. Since  the migratory  rate 
of proteins  greatly  decreases as the pore size  of acrylamide  approaches their 
radius, gradient deoxycholate-PAGE is likely to separate proteins domi- 
nantly according  to size. Some proteins with positive or weakly negative 
charge may migrate  anomalously,  since sodium  deoxycbolate  may not con- 
fer an overall negative  charge to all proteins. 
Immunodetection  of LTBP and TGF-B1 from both sodium  deoxycholate 
and SDS-PAGE filters was performed essentially  as described (Talpale et 
al., 1992). The filters were blocked  by PBS containing  1% TX-100  and 5% 
nonfat  milk powder. The filters were then reacted with antibodies,  washed, 
and bound  antibodies  were detected using  biotin-streptavidin  amplification 
and enhanced chemiluminescence  detection (ECL; Amersham). Incuba- 
tions and washes were carded out in 50 mM Tris-HCl  buffer, pH 8.5, con- 
taining 0.5 M NaCl, 0.1% BSA, and 0.1% Tween  20. 
Results 
LTBP Is Associated with the ExtraceUular Matrix of 
Fibroblasts and b~brosarcoma Cells 
To determine whether LTBP is associated with the extracel- 
lular matrix,  we labeled HT-1080 fibrosarcoma cells with 
[35S]cysteine  for  three  days  (see  Materials and Methods). 
The cells were then washed, changed to serum free medium, 
followed by treatment with plasmin (1  CU/ml) at 37°C for 
1 h.  The plasmin concentration used releases over 90% of 
matrix-associated TGFo/31 in 30 min (Taipale et al.,  1992). 
The medium was collected and plasmin was inhibited  by pro- 
teinase inhibitors. LTBP was immunoprecipitated from the 
medium with specific antibodies (see Materials and Meth- 
ods). Analysis of the precipitated material by 4-20 % SDS- 
PAGE under reducing conditions followed by autoradiogra- 
phy revealed that LTBP immunoreactivity  is rapidly released 
from the cell layer by plasmin (Fig. 1). Two major and a mi- 
nor polypeptides (140-180 kD) were observed in the auto- 
radiogram. 
Subsequently,  we prepared extracellular matrices from the 
respective  cells  by  sodium  deoxycholate  extraction  (see 
Materials and Methods). (Note that since sodium deoxycho- 
late insoluble fraction of cells contains both substratum at- 
tached proteins and proteins derived from the extracellular 
matrix, we cannot differentiate between these two. The term 
"extracellular matrix" is therefore used synonymously with 
"sodium  deoxycholate  insoluble fraction"  throughout  the 
text.) Immunoprecipitation  analysis of these preparations af- 
ter solubilization  with 8 M urea, 100 mM NaOH or 1% SDS 
and dilution to non-denaturing conditions revealed no de- 
tectable LTBP immunoreactivity (data not shown). The ob- 
served release of LTBP immunoreactivity  (Fig. 1) could not 
be explained by release from the cell surface, since sufficient 
amounts of LTBP were not found in cell lysates containing 
cell surface bound proteins (data not shown). 
To resolve the question whether LTBP is bound to the ex- 
tracellular matrix, we used immunoblotting analysis to de- 
termine the approximate amount of LTBP released by plas- 
min. Confluent cultures of human lung fibroblasts, which 
build heavy meshworks of extracellular matrix, were changed 
to serum free medium and treated with plasmin. Extraeellu- 
lar matrices were prepared from the same ceils by sodium 
deoxycholate  extraction.  Compared  with  the  amount  of 
LTBP released by plasmin (see below), only very low levels 
Figure 1.  LTBP is associated 
with the cell layer. Immuno- 
precipitation  analysis  of LTBP 
released from the cell layer by 
plasmin.  Extracellular  ma- 
trices of HT-1080 ceils  were 
labeled by culturing the cells 
in the  presence  of  [JSS]cys- 
teine for 3  d  (see  Materials 
and Methods).  The cells were 
subsequently  treated  with 
plasmin  (1 CU/ml) at 37°C for 
1  h  as  indicated  (+).  The 
medium  was  collected  and 
plasmin activity  was neutral- 
ized by 1 mM PMSF and 200 
IU/ml  aprotinin.  LTBP  was 
immunoprecipitated from the 
medium with  an LTBP  spe- 
cific  antibody  (Ab-39)  with 
(+) or without competing  unlabeled  platelet LTBE The precipitates 
were analyzed on 4-20 % gradient SDS-PAGE under reducing con- 
ditions, followed by fluorography. Plasmin  treatment is indicated on 
the top of the figure (+). The mobilities  of molecular mass markers 
(kD) are indicated on the left. Note that TGF-/31 and LAP are not 
visible in this fluorogram  due to weak labeling of the respective 
proteins (low content of cysteine). 
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the  extracellular  matrix  and  its 
release  by  plasmin.  (A)  Plasmin 
releases  covalently  bound  LTBP 
from fibroblast extracellular matrix. 
Extracellular  matrices  were  pre- 
pared  from human lung fibroblasts 
by sodium deoxycholate extraction 
(see  Materials  and  Methods).  The 
extraceUular  matrices were collected 
in 1% SDS with or without prior par- 
tial digestion with plasmin (0.3 CU/ 
ml,  37°C for  1 h)  and  solubilized 
by heating to 95°C. SDS-insoluble 
material was pelleted from two untreated matrices by ultracentrifugation (see Materials and Methods). The pellets were treated with plasmin 
(0.3 CU/ml) or control buffer. SDS-containing sample buffer was added and the samples heated again to 95°C. The samples were then 
analyzed by 5-15% gradient SDS-PAGE under nonreducing conditions, followed by immunoblotting analysis, using anti-LTBP antiserum 
(Ab-39). All lanes are from a single exposure of one filter and represent material derived from 10 cm  2 of extracellular matrix. Standard 
(S) contains 10 ng of purified platelet LTBP. Plasmin treatment is indicated on the top of the figure (+). Note that plasmin treatment in- 
creased the amount of LTBP immunoreactivity in the matrix preparations 10--100-fold,  and revealed the presence of LTBP also in the SDS- 
insoluble pellet fraction. (B) Analysis of the complex structure of plasmin released latent TGF-/31 by deoxycholate-PAGE.  Confluent cul- 
tures of  human fibroblasts were changed to serum free medium, and the conditioned medium prepared in the presence or absence of  plasmin 
(0.01 CU/ml), was collected after 3 d. The molecular nature of secreted TGF-/~  1 complexes was analyzed from the concentrated conditioned 
medium (500 #l/lane) by sodium deoxycholate-PAGE  followed by immunoblotting with antibodies specific for "I'GF-/~I and LTBP as indi- 
cated in the figure (see Materials and Methods for details). Both chemiluminescence signals are from the same filter. TGF-/~I was detected 
first (5-min exposure) followed  by washing and detection of LTBP (3-s exposure). Arrow represents the bottoms of the sample wells (stack- 
ing gel was not used). 
were detectable in the untreated matrix preparations by im- 
munoblotting (data not shown), indicating that LTBP is ei- 
ther masked or cross-linked to very high molecular weight 
form that does not enter the gel. 
Previous cross-linking experiments suggested that matrix- 
bound TGF-~I is cross-linked to very high molecular weight 
complexes (see Taipale et al.,  1992).  Highly cross-linked 
complexes formed by disulfide linkages and covalent associa- 
tion  of  proteins  catalyzed  by  lysyl  oxidase  and  trans- 
glutaminase are known to be present in the ECM (see Keski- 
Oja et al.,  1976; Hedman et al., 1979; Reiser et al., 1992). 
These cross-linked complexes appear as particulate material 
that is not dissociated by heat treatment in the presence of 
SDS.  To determine whether LTBP is a  component of the 
fibroblast  SDS-insoluble  extracellular  matrix,  we  treated 
isolated extraceUular matrices with plasmin (0.3 CU/ml) at 
37°C for 1 h to partially digest the extracellular matrix prior 
to  solubilization of the matrix in  SDS containing sample 
buffer (see Materials and Methods). Immunoblotting analy- 
sis indicated that ~10-100-fold higher levels of LTBP im- 
munoreactivity were present in the matrix digest compared 
to a conventional matrix preparation (Fig. 2 A, Matrix). In 
subsequent experiments, we were able to immunoprecipitate 
LTBP and LAP from the supernatant fluids of isolated ex- 
tracellular matrix preparations treated with plasmin. 
To confirm that  LTBP is  present  in  the  SDS-insoluble 
matrix  fraction,  we  prepared extracellular matrices  from 
confluent fibroblasts by sodium deoxycholate  extraction, and 
solubilized them to 1% SDS by treatment at 95°C for 5 min. 
The  matrix  preparations  were  then  centrifuged to  pellet 
SDS-insoluble material, and the pellets washed with PBS to 
remove excess SDS. The pellets were subsequently treated 
with plasmin or control buffer, and immunoreactive LTBP 
was assayed by immunoblotting (see Materials and Meth- 
ods). A small amount of LTBP immunoreactivity was recov- 
ered from the pellet by the plasmin treatment (Fig. 2 A, Pel- 
let),  indicating that at least some LTBP is present in the 
cross-linked extracellular matrix (ECM).  Since heat treat- 
ment in SDS denatures proteins and renders them very sensi- 
tive to proteinases, quantitative recovery by this method is 
not practical. These results suggest that LTBP is associated 
covalently with the extracellular matrix, either by disulfide 
bond(s), or reducible or nonreducible cross-links formed by 
matrix cross-linking enzymes. Since the anti-LTBP antibody 
(Ab-39) does not react with LTBP under reducing condi- 
tions, we were unable to determine the exact molecular na- 
ture of the bond between LTBP and the extracellular matrix. 
To analyze the  complex structure of latent TGF-~  re- 
leased by plasmin, we used novel analysis method consisting 
of  sodium  deoxycholate-PAGE and  immunoblotting  (see 
Materials and Methods).  Fibroblast cultures were washed 
with serum-free medium and incubated with or without 0.01 
CU/ml plasmin for 3  d  under serum-free conditions. The 
conditioned medium was subsequently concentrated 30-fold 
by centrifugal ultrafiltration (Centriprep 3; Amicon Corp., 
Beverly, MA). Immunoblotting analysis of  the medium using 
sodium  deoxycholate-PAGE with  antibodies  specific  for 
LTBP and TGF-B1 indicated that TGF-~I is bound to a spe- 
cies co-migrating with a minor component of LTBP (,,o200 
kD), ~100 kD larger than the major LTBP species (Fig. 2 
B). These results suggest that fibroblasts secrete an excess 
of LTBP, and that only a fraction of LTBP is associated to 
the  small  latent  TGF-/31  (LAP.TGF-/~I) complex.  These 
results also suggest that soluble proteins migrate in gradient 
sodium  deoxycholate-PAGE  similarly  to  gradient  SDS- 
PAGE. Since TGF-~ did not dissociate from/~I-LAP during 
electrophoresis, sodium deoxycholate-PAGE can be used to 
study the molecular complexes of TGF-B1.  The molecular 
weights obtained are, however, highly approximate (actually 
an upper limit) due to nondenaturing nature of this gel sys- 
tem. The active form of TGF-~I, a highly hydrophobic and 
positively charged protein, obtained by heat treatment of the 
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matrix by plasmin. Confluent cultures of  HT-1080  cells were treated 
for 30 min with increasing concentrations of plasmin under serum- 
free conditions. LTBP and TGF-B1 were assayed from the condi- 
tioned medium (Released), extracellular matrix preparations (Ma- 
tr/x, SDS-soluble, sodium deoxycholate insoluble cell extrac0, and 
isolated extracellular matrices digested with plasmin prior to addi- 
tion of SDS (Matrix  Digest, see Materials and Methods for details) 
by  immunoblotting (nonreducing 4-20%  gradient  SDS-PAGE). 
Immunoblotting was first carried out using anti-LTBP antibodies 
and subsequently anti-TGF-/51 antibodies. All signals are from the 
same filter (separate exposures for LTBP and TGF-B1). Specific 
bands are shown. Released  and Matrix  Digest samples contain pro- 
teins derived from 1 cm  2 of cell culture, while 2 cm  2 of matrix was 
loaded to lanes Matrix for clarity. The concentrations of plasmin 
in the figure refer to the original concentration of plasmin (CU/ml) 
used to release LTBP from the cells prior to matrix preparation by 
sodium deoxycholate extraction. In Matrix  Digest the second treat- 
merit with plasmin was 0.3 CU/ml at 37°C for 30 min. Standard 
(S) lane contains approximately equimolar amounts of  purified hu- 
man platelet LTBP (8 ng) and TGF-B1 (1 ng). 
conditioned medium,  did not migrate at 25 kD  in deoxy- 
cholate-PAGE, but aggregated on the top of the gel (data not 
shown).  The reason for this is unclear at present. 
LTBP and TGF-B1 Are Co-released from the 
ExtraceUular Matrix of  HT-1080 Cells by Plasmin 
To analyze the interrelationships between LTBP and TGF-B1, 
confluent cultures of HT-1080 cells were treated with in- 
creasing concentrations of plasmin for 30 min under serum- 
free conditions. The medium was collected and plasmin was 
inhibited by the addition of PMSF and aprotlnin. Alterations 
in the amounts of released LTBP and TGF-B1 were analyzed 
by  immunoblotting  (see  Materials  and  Methods).  It  was 
found that the amounts of LTBP and TGF-BI released to the 
supernatant increased in a dose-dependent manner and con- 
comitantly as a  function of plasmin concentration (Fig.  3, 
Released).  The molar amounts of LTBP and TGF-B1 sug- 
gested that there is an excess of LTBP in the matrix. The size 
of LTBP (170-120 kD) decreased stepwise suggesting that 
several proteolytic cleavages may occur (Fig. 3, Released). 
The final fragment of digestion was in the same range as the 
platelet LTBP used as standard (Fig. 3, lane S; 120-140 kD). 
The molecular weight of TGF-/~I did not decrease during the 
experiment, as reported earlier (Lyons et al.,  1990; Taipale 
et al.,  1992). 
To analyze the relative amounts of TGF-B1 and LTBP in 
the matrix,  extracellular matrices were prepared from the 
respective cells by extraction with sodium deoxycholate and 
analyzed by immunoblotting.  The amount of TGF-B1  was 
found to decrease in these matrix preparations with increas- 
ing plasmin concentrations as shown earlier (Taipale et al., 
1992).  Only low amounts  of immunoreactive LTBP were 
found in  the matrices of untreated cells,  but the level of 
120-140 kD LTBP increased with increasing plasmin dose 
(Fig.  3, Matrix).  Immunoreactive LTBP thus probably ap- 
peared in the matrix preparations due to cleavage(s) from the 
high molecular weight cross-linked insoluble form that does 
not enter the resolving gel. The reason why this minor frac- 
tion of LTBP is cleaved but remains associated to the matrix 
is unclear at present. The result does not imply that TGF-B1 
and LTBP would be released from the matrix independently, 
since TGF-B1 is released from the latent complex by SDS 
used in the preparation of the SDS-PAGE sample (Miyazono 
et al.,  1988). 
To determine whether LTBP released to the supernatant 
by plasmin is derived from the SDS-insoluble extracellular 
matrix, we treated HT-1080 cells with the same doses of  plas- 
min as above and isolated the extracellular matrices. Here, 
instead of directly collecting the matrices, we treated these 
isolated matrices again with a constant concentration of  plas- 
min (0.3 CU/mi) to partially digest the extracellular matrix 
(see Matrix Digest in Materials and Methods) and unmask 
covalently bound LTBP before addition of SDS containing 
buffer (see above). Analysis of these preparations by immu- 
noblotting indicated  that  the initial plasmin  treatment re- 
suited in  concomitant, dose dependent loss of LTBP and 
TGF-B1 from these matrix preparations (Fig. 3, Matrix Di- 
gest). Comparison of  the amounts of LTBP released from the 
cell  layer to  the  supernatant  (Fig.  3,  Released)  and  the 
amount of total LTBP present in  the extracellular matrix 
(Fig. 3, Matrix Digest), indicate that a major fraction ofplas- 
min released LTBP is derived from the extracellular matrix. 
Slightly lower amounts of LTBP were however found in the 
solubilized matrix (Matrix Digest)  than in the supernatant 
(Released).  This is probably due to losses occurring during 
the preparation of  the matrices and during plasmin digestion. 
In earlier experiments (Taipale et al.,  1992) the recovery of 
TGF-~I from the matrix was ~70--80%. We cannot, however, 
rule  out  the  possibility  that  plasmin  could  release  some 
LTBP from the cell surface as well. Comparison between the 
levels of LTBP and TGF-/~I also suggest that there is an ex- 
cess of LTBP in the matrix (see below). 
Secreted Large Latent TGF-[3 Complex 
Associates with the Extracellular Matrix 
Rapidly After Secretion 
To study the kinetics of latent TGF-B association with the ex- 
tracellular matrix, we performed pulse-chase experiments. 
Subconfluent,  actively growing cultures of HT-1080 cells 
were incubated in serum free MEM for 1 h to remove serum 
proteins. The cells were subsequently labeled with [35S]cys- 
teine (500/zCi/ml) for 10 rain (see Materials and Methods), 
washed twice, and chased with MEM (>500-fold excess of 
unlabeled cysteine) as indicated (Fig. 4). The medium was 
then collected and the cells were lysed with 0.5%  sodium 
deoxycholate containing buffer. Extracellular matrices were 
prepared from the same cells, and treated with plasmin to 
release LTBP covalently bound to the matrix. Cell lysates, 
extracellular matrix digests (see Materials and Methods) and 
the medium were analyzed by immunoprecipitation with an- 
tibodies specific for the small latent TGF-~ complex (LT-2) 
and LTBP (Ab-39). The specificity of the LAP (LT-2) bands 
was judged by precipitation with LT-2 in the presence of 
competing unlabeled antigen. 
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matrix of HT-1080  ceils. Cultures of HT-1080  ceils (70 % confluent) 
were changed to serum-free medium and incubated in cysteine- and 
methionine- free MEM for 30 rain to deplete intracellular Ix~ols 
of cysteine.  Ceils  were  subsequently labeled  with  500  ttCi/ml 
[35S]cysteine in cysteine-free MEM  for  I0 min.  The cells were 
then washed rapidly two times and chased with MEM (>500-fold 
excess of unlabeled cysteine). Medium was then collected and the 
cells were lysed with sodium deoxycholate containing buffer (see 
Materials and Methods) at the time points shown on the figure. Ex- 
tracellular matrices were prepared from the same cells and treated 
with plasmin (0.3 CU/ml) at 37°C for 1 h to release latent TGF-# 
complexes covalently bound to the matrix. The medium, cell ly- 
sates and extracellular matrix digests were incubated with antibod- 
ies specific for LTBP (Ab-39) and LAP (LT-2)  followed by precipi- 
tation of immune complexes by protein A-Sepharose beads. The 
precipitates  were analyzed by 4-15 % gradient SDS-PAGE under 
nonreducing conditions followed by fluomgraphy. The specificity 
of precipitation was assessed by precipitation with anti-LAP anti- 
bodies in the presence of competing antigen. The positions of the 
specific complexes and a single background band probably repre- 
senting fibronectin (FN) are also indicated. The mobilities of the 
molecular mass markers (kD) are shown on the left. (A) Cell ly- 
sates; (B) material released from the pericellular matrix by plas- 
min. Immunoprecipitation analysis of the medium was negative. 
Analysis  of  the  material  immunoprecipitated  by  anti- 
LTBP antibodies in 4-15 % gradient SDS-PAGE under non- 
reducing conditions, followed  by fluorography, indicated that 
after 12 min of  chase, all detectable radioactivity was present 
in the cell lysate (Fig. 4 A, a. LTBP lanes). A predominant 
band of 180 kD and a less intense band of 250 kD were ob- 
served (Fig. 4 A). The 180-kD band represents free LTBP, 
while the 250-kD band is evidently a complex between LTBP 
and LAP, since it was also present in the immunoprecipitate 
obtained by anti-LAP antibodies (Fig. 4 A, a. LAP lanes). 
Under reducing conditions, the 250-kD band was reduced to 
180-kD (gel not shown), which is in accordance with the 
finding that LTBP and LAP are bridged by a disulfide bond 
(Miyazono et al., 1988, 1991). A component of ~45 kD, cor- 
responding in size to the nascent, uncleaved chain of pro- 
TGF-fl, was also observed in the anti-LAP immunoprecipi- 
tates after 12 min of chase (Fig. 4 A, lanes a .LAP). After 
2  h  of chase, this band is converted to a disulfide bonded 
dimer of 90 kD (Fig. 4  A; see Miyazono et al.,  1991).  In 
addition to the 250-kD band representing LAP-LTBP com- 
plex, two specific bands of 195 and 200 kD were also de- 
tected in the anti-LAP immunoprecipitates. These compo- 
nents  were not present  in  the  material  precipitated  with 
anti-LTBP antibodies,  suggesting that they represent com- 
plexes between LAP and a  high molecular weight protein 
that is distinct from LTBP (see Olofsson et al.,  1992). Two 
nonspeciflc bands, a low molecular mass species migrating 
slightly above the 30-kD marker, and a high molecular mass 
band, probably representing fibronectin (denoted FN), was 
also present in some of the immunoprecipitates (Fig. 4 A). 
After 2 h of  chase, the majority of  LTBP immunoreactivity 
was lost from the cell lysate, while approximately equal lev- 
els of LAP immunoreactivity were present in the samples 
collected at 12 min and 2 h. This is consistent with earlier 
results showing that the free form of LTBP and LTBP com- 
plexed to latent TGF-~  are secreted rapidly, while latent 
TGF-/~  not  containing  LTBP  is  retained  intraceUularly 
(Miyazono et al., 1991, 1992). Since the cell lysates contain 
also cell surface bound material, these results also suggest 
that significant amounts of LTBP do not remain associated 
with the cell layer due to association with cell surface alone. 
After 2  h  of chase,  the major of fraction of LTBP im- 
munoreactivity was found in association with the extracellu- 
lar matrix, while negligible levels of immunoreactivity were 
present  in  the  medium  (data  not shown).  Two groups  of 
LTBP related components were precipitated from the ex- 
tracellular matrix released material,  representing the free 
form of LTBP (100-130 kD) and LTBP complexed to LAP 
(200 kD; Fig. 4 B). The 200-kD component was also detect- 
able in the anti-LAP immunoprecipitates (Fig. 4 B). A very 
weak band of 25  kD  corresponding TGF-/~, as judged by 
comigration with ~25I-TGF-~l, was also detectable in the flu- 
orograms  of both the  anti-LTBP and  anti-LAP  immuno- 
precipitates. 
These  results  indicate  that  in  actively  growing,  sub- 
confluent cells, secreted free form of LTBP and LTBP com- 
plexed to latent TGF-/~ rapidly associate with the extracel- 
lular matrix. The difference between the migration of free 
LTBP here and above (Fig. 1) is due to the fact that the free 
form of LTBP migrates as a component of slightly lower mo- 
lecular weight under nonreducing than under reducing con- 
ditions (Miyazono et al.,  1991). 
Free and TGF-~l-bound Forms of  LTBP  Are Released 
from the Extracellular Matn'x by Plasmin 
To study the effects of plasmin on the association of LTBP 
with the extracellular matrix, we pulse labeled subconfluent 
HT-1080 cultures with psS]cysteine (200/zCi/ml) for 1 h. 
The cultures were subsequently chased with MEM contain- 
ing a relatively low concentration of plasmin (0.03 CU/ml). 
Medium and extracellular matrix digests were analyzed by 
immunoprecipitation with the LTBP specific antibody fol- 
lowed  by  SDS-PAGE  under  nonreducing  conditions  and 
fluorography. Inspection of the fluorograms indicated that in 
control cells LTBP was associated with the extraceUular ma- 
trix, reaching peak levels after 7 h  of chase (Fig.  5 A). A 
component comigrating with  t25I-TGF-/~l was also seen in 
the matrix after 7 and 26 h of chase. Substantial amounts of 
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tracellular matrix of HT-1080 cells. Cultures of HT-1080 cells were 
labeled with 200 #Ci/ml [35S]cysteine in cysteine-free MEM for 1 
h.  The cells were washed two times and chased with MEM with 
or without  plasmin (0.03 CU/ml).  Medium  was collected  after 
different chase periods and plasmin activity was neutralized by pro- 
teinase inhibitors.  Extracellulax matrices  were prepared  from the 
respective  cells and treated  with plasmin  to release  LTBP cova- 
lently bound to the matrix (see Materials and Methods). LTBP was 
immunoprecipitated  from the  cell  supernatant  and  extracellular 
matrix digests, and the precipitates  were analyzed by 4-15%  gra- 
dient SDS-PAGE under nonreducing conditions followed by fluo- 
rography. Specificity of precipitation was assessed by precipitation 
with unrelated  control  serum.  The migration  of molecular  mass 
markers (kD) is shown on the left. A plasmin sensitive background 
band probably representing fibronectin is denoted by FN. Positions 
of the  specific complexes  and  125I-TGF-/51 used  as  standard  are 
indicated. 
Figure 6. Association of exog- 
enous LTBP to the extracellu- 
lax matrix of  growing HT-1080 
fibrosareoma  cells.  Human 
lung fibroblasts were grown to 
confluency  and  changed  to 
serum-free  medium  for  the 
collection of  soluble fibroblast 
derived proteins.  Cell-conditioned  medium was produced  by in- 
cubating the cells in MEM containing 1% of the normal amount of 
methionine  and  cysteine with  or without  [35S]cysteine (see Ma- 
terials  and Methods).  The conditioned medium was collected by 
centrifugation and treated with plasmin (+). Plasmin was inhibited 
by the addition of  proteinase inhibitors. Radiolabeled and unlabeled 
plasmin  treated  and untreated  conditioned  media were mixed to 
generate samples representing all possible plasmin treatment varia- 
tions containing equal amounts of radioactivity. To prepare recipi- 
ent cells, actively growing, subeonfluent cultures of HT-1080 cells 
were changed to serum free medium and treated with plasmin (+) 
or medium alone, followed by inhibition of  protein synthesis by cy- 
cloheximide. Samples of fibroblast conditioned medium, prepared 
as above, were diluted to MEM containing cysteine (1:1) and incu- 
bated with the HT-1080  cultures for 1  h. Subsequently, extracellular 
matrices were prepared from the HT-1080 cells (see Materials and 
Methods)  and analyzed  by immunoprecipitation  with antibodies 
specific for LTBP (Ab-39). The immunoprecipitates were analyzed 
by 5-15%  SDS-PAGE under  nonreducing conditions followed by 
fluorography. All  samples  thus  contain  HT-1080 cultures  and  a 
similar amount of metabolically labeled and unlabeled conditioned 
medium.  Treatments of the HT-1080 cells  (Cells) and  fibroblast 
conditioned media (Labeled CM and Cold CM) by plasmin,  prior 
to mixing and incubation,  axe indicated by (+). Note that the as- 
sociation of radioactive LTBP, derived from the fibroblast condi- 
tioned medium, to the ECM of HT-1080 cells is totally abrogated 
in  all  incubations  where  labeled  conditioned  media  had  been 
pretreated  with plasmin (lanes 3, 5, and 6). 
LTBP immunoreactivity were not observed in the medium 
until after 26 h  (Fig. 5 A). At this time point several LTBP 
immunoreactive components between 100 and 200 kD were 
observed,  suggesting that LTBP is cleaved by endogenous 
proteinases. 
In contrast,  when plasmin (0.03  CU/mi) was included in 
the chase solution,  two groups of components of 180-200 
kD and 110-130 kD were precipitated from the medium even 
after  1  h  of chase.  The  intensities  of these  components 
reached a peak after 7 h chase (Fig. 5 B). The 180-200 kD 
components  represent  LTBP  complexed  to  /31-LAP  (see 
above), while the lower group of components represents the 
free form of LTBP.  The free form of LTBP and LTBP com- 
plexed to LAP.TGF-/3 were present in roughly 10:1 ratio. The 
relative intensities of the bands may, however, not reflect the 
actual levels of these complexes, since binding of LTBP to 
LAP is likely to mask some immunoreactive epitopes and 
hence decrease the binding of the antibodies.  After 7  h  of 
chase,  a  25-kD  band  representing  TGF-/31 (as judged  by 
specificity of precipitation and comigration with  ~25I-TGF- 
~)  was also detected (Fig.  5 B). 
Associaffon of Exogenous LTBP with the Matrix 
To determine whether the release of latent TGF-/5'I occurs by 
cleavage of LTBP or the LTBP binding component in the ex- 
tracellular matrix, we studied the association of exogenous 
radioactive LTBP with the extracellular matrix of HT-1080 
cells. Although low to negligible levels of immunoreactive 
LTBP were detected by immunoprecipitation from the cul- 
ture  supernatants  of subconfluent,  actively  growing  cells 
(above), confluent, resting cultures of fibroblasts were found 
to  secrete relatively large fraction (50-80%)  of produced 
LTBP immunoreactivity in 16 h (data not shown). The con- 
ditioned  medium  of  [35S]cysteine  labeled  fibroblasts  was 
thus  used  as  a  source  of soluble  radioactive  LTBP  (see 
Materials  and  Methods).  To obtain unlabeled conditioned 
medium control cells were treated identically but radioactive 
cysteine was omitted. The cell conditioned medium was col- 
lected, clarified by centrifugation and treated with plasmin 
(0.1 CU/ml) at 37°C for 1 h  as indicated.  Plasmin was in- 
hibited by the addition of proteinase inhibitors, and the incu- 
bation was continued for 30 min. Radioactive and unlabeled 
conditioned media, treated or not with plasmin, were mixed 
to yield samples containing equal amounts of radioactivity 
(see Fig.  6).  The samples were then added to the medium 
of subconfluent cultures of HT-1080 whose protein synthesis 
had been inhibited by pretreatment with cycloheximide (5 
/~g/ml,  5 min), and incubated at 37°C for 1 h. Before addi- 
tion  of  labeled  conditioned  media,  some  cultures  were 
treated with plasmin (0.1 CU/mi) at 37°C for 1 h to partially 
digest the  extracellular  matrix as  indicated  on the  figure. 
Subsequently, extracellular matrices were prepared from the 
HT-1080 cells and immunoprecipitation analysis was carded 
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for details). 
In control cells incubated with untreated radioactive con- 
ditioned  medium  mixed  with  untreated  unlabeled  condi- 
tioned medium, significant amounts of LTBP were found to 
associate with the matrices of HT-1080 cells (Fig. 6, lane/). 
While plasmin treatment of the recipient cells slightly en- 
hanced LTBP association (Fig. 6,  lane 2), treatment of la- 
beled  conditioned medium  by  plasmin  totally  abrogated 
binding of radioactive LTBP to the ECM (Fig. 6, lanes 3, 5, 
and  6).  When  radioactive untreated conditioned medium 
was mixed with nonradioactive plasmin treated conditioned 
medium, the association of radioactive LTBP to the ECM 
was inhibited only partially (Fig. 6, lane 4), indicating that 
plasmin preparation or proteolytic products of the condi- 
tioned medium are not responsible for the inhibition of LTBP 
binding to the extracellular matrix. The partial inhibition of 
binding  could be due to degradation of other soluble ex- 
tracellular matrix components required for proper matrix as- 
sembly. Note that the banding pattern of LTBP in all lanes 
is identical because the matrices were solubilizzd by limited 
plasmin digestion before immunoprecipitation. 
Discussion 
The present results indicate that latent TGF-/~I (LAP.TGF- 
/~l) is bound to the extracellular matrix of cultured fibroblasts 
and fibrosarcoma cells via LTBP. The association between 
LTBP and the extracellular matrix is mainly covalent, and 
the major fraction of LTBP cannot be released from the ma- 
trix even by heat treatment in SDS. Immunoreactive LTBP 
can  be  released  from  the  matrix,  however,  by  plasmin- 
mediated proteolysis. On the other hand, TGF-/~I is released 
from the extracellular matrix preparations by SDS, indicat- 
ing  that  TGF-/31  is  noncovalently associated  to  /~I-LAP, 
which in turn binds to LTBP by a  disulfide-bond, as de- 
scribed earlier for the soluble, platelet form of latent TGF-~ 
(Miyazono et al.,  1988; Wakefield et al.,  1988). 
In accordance with previous findings  (Miyazono et al., 
1991,  1992),  our  pulse-chase  experiments  revealed  that 
the  synthesized LTBP is  secreted relatively rapidly  from 
HT-1080 ceils, while the secretion of LAP is slower.  After 
secretion, the major fraction of LTBP associates with the ex- 
tracellular matrix, and only traces of LTBP immunoreactive 
material are detectable in the culture medium. Both the free 
form of LTBP, and LTBP complexed to LAP-TGF-/31  were 
found associated with the ECM. Exogenous LTBP from the 
conditioned medium of fibroblasts also associated with the 
matrix of HTA080 cells, and the association was inhibited by 
plasmin pretreatment of the conditioned medium. Treatment 
of  the celt layers with plasmin, in contrast, slightly enhanced 
the binding of exogenous LTBP to the extracellular matrix. 
These results indicate that secreted large latent TGF-/31 as- 
sociates with the extracellular matrix via LTBP, and/31-LAP 
or TGF-fll are not necessarily required for the interaction. 
The release of latent TGF-131 is likely to be due to a cleavage 
of LTBP between the domains involved in binding/31-LAP 
and  the  extracellular matrix  (schematically  illustrated  in 
Fig. 7). The molecular character of these domains and the 
proteins to which LTBP is bound in the extracellular matrix 
is not understood at present. The results do not, however, 
exclude the  possibility  that  also  the  small  latent TGF-ffl 
Figure  7. Proposed structure of matrix-associated latent TGF-/51. 
A schematic representation of the proposed structure of extracellu- 
lar matrix-associated latent TGF-fll. TGF-fll dimer is bridged by 
a single disulfide bond (cys  77-77 of the mature sequence in TGF- 
/32) (Daopin et al., 1992; Schlunegger et al., 1992). ill-LAP dimer 
is held together via cysteine residues 223 and 225, and the dimer 
is associated to TGF-/51 by noncovalent interactions, rendering the 
complex latent. LTBP is associated to the extracellular matrix cova- 
lently, and to the small latent TGF-B  1 complex by disulfide bond(s). 
Unknown cysteine residue in LTBP binds probably to eys-33 in/51- 
LAP, since this cysteine is not involved in LAP-dimer formation, 
and forms an anomalous disulfide bond with active TGF-/51 in 
recombinant latent TGF-/51 (see Brunner et al.,  1989). Proposed 
proteinase sensitive hinge region, rich in proline and basic residues 
(amino acids 413-506),  separates LTBP domains responsible for 
binding to LAP and to the extracellular matrix. Plasmin cleavage 
of this hinge region results in the formation of soluble large latent 
TGF-/51 complex, containing an ~135-kD fragment of  LTBP,  while 
an ,~50-kD fragment possibly remains associated to the extraeelh- 
lar matrix. An additional cleavage  occurs later, resulting in an ,~10- 
kD decrease in molecular weight of the large fragment (see Fig. 5 
B, Medium, LAP+LTBP). Proposed cleavage  sites at human LTBP 
are a tribasic (RRRP;  0)) site starting at amino acid 415 and di- 
basic site (RR;  (~) at  1257, respectively (Kanzaki et al.,  1990; 
Tsuji et al., 1990). In cells that store latent TGF-B, LTBP could be 
cleaved at these sites by processing endoproteinases that are exclu- 
sively present at the regulated secretory pathway, like PC2 and 
PC1/3 (see Barr, 1991; Nakayama  et al., 1992; Steiner et al., 1992). 
An additional site that resembles a monobasic site cleaved by PC1/3 
is also present in the human, but not rat, LTBP sequence (starting 
at amino acid 461, REHGARS;  ®) (see Nakayama et al.,  1992). 
Small ovals represent disulfide bridges. 
complex (LAP.TGF-/31) could interact with the extraceUular 
matrix. 
Active TGF-/31 binds to multiple extraeelhlar matrix com- 
ponents,  including type IV collagen,  fibronectin, and the 
proteoglycans betaglycan, endoglin and decorin (Paralkar et 
al.,  1991;  Fava  and  McLure,  1987;  Massagu6  and  Like, 
1985; Cheifetz et ai.,  1992; Yamaguchi et al.,  1990). Our 
results, however, indicate that the association of TGF-/31 to 
the extraceUular matrix after secretion do not require a prior 
activation step. Active TGF-/31 is a highly hydrophobic and 
basic protein, and is rapidly lost from solution (Brown et al., 
1990); it therefore binds to many proteins with a relatively 
high  affinity.  However,  the  physiological  significance  of 
some  of these  interactions remains  to  be  shown.  Matrix 
components binding  active TGF-/31  could have  a  role in 
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delivering it to the cell surface receptors (see Wang et al., 
1991; L6pez-Casillas et al.,  1993),  as in the case of basic 
fibroblast growth factor (Flaumenhaft et al., 1990; Yayon et 
al.,  1991). 
Olofsson et al. (1992) found that glioblastoma cells secrete 
three forms of latent TGF-B1. The small latent TGF-B1, con- 
tains only El-LAP and TGF-BI, while of the two large latent 
complexes, one contains LTBP and the other a protein im- 
munologically distinct from LTBP. These high molecular 
weight binding proteins could target latent TGF-E's to other 
extracellular localizations (for immunolocalization of TGF- 
E's,  see Thompson et al., 1989;  Heine et al., 1990;  Pelton 
et al., 1991). Our results indicate that the association of TGF- 
E1 to the fibroblast form of LTBP results in targeting of latent 
TGF-E1 to the ECM. Also TGF-E2 and TGF-E3 have been 
found in complex with LTBP (Olofsson et al., 1992). These 
two TGF-E isoforms thus probably bind to fibroblast-type ex- 
tracellular matrices via LTBP. In addition, our model cells, 
human lung fibroblasts and HT-1080 fibrosarcoma, seem to 
produce an excess of LTBP which could serve as a matrix 
receptor for small latent TGF-Es  (LAP.TGF-E). 
Fibroblasts  synthesize  a  high  molecular  mass  LTBP 
(170-190  kD),  while  platelet c~-granules  contain  smaller 
LTBP (140 kD) that lacks amino- and/or carboxy-terminal 
sequences (Kanzaki et al., 1990; Tsuji et al., 1990).  Cleav- 
age of large LTBP by plasmin (and trypsin, see Miyazono et 
al., 1991) results in the formation of components very simi- 
lar in size to the platelet form. Our data suggests that plasmin 
cleavage results in the formation of a soluble "platelet-like" 
LTBP fragment and a domain that may remain associated to 
the ECM. Similar cleavages of LTBP could also occur on the 
regulated secretory pathway or in the or-granules of platelets 
(see legend to Fig. 7). Platelet degranulation would thus re- 
sult in the formation of a large but transient pool of activat- 
able TGF-E to the vicinity of damaged tissues, while latent 
TGF-jSq, stably incorporated to the ECM, could serve a more 
general purpose, possibly acting as a feedback regulator in 
cell invasion and ECM formation (see Saksela and Rifkin, 
1988; Keski-Oja et al.,  1991). Interestingly, mice defective 
in both TGF-~I alleles die due to invasion of inflammatory 
cells in various internal organs (Shull et al., 1992; Kulkarni 
et al., 1993). It is possible that the lack of TGF-/~I in the ex- 
tracellular matrix, resulting in the lack of inhibitory feed- 
back to matrix degradation, contributes to the phenotype of 
these mice. Defective feedback by TGF-~I can also be im- 
portant in tumor invasion, since some tumor cells respond 
to  TGF-E1 aberranfly,  by  increasing  proteolytic  activity 
(Keski-Oja et al.,  1988a,b). 
The interrelationships between matrix association and ac- 
tivation of TGF-B1 remain to be determined. Recombinant 
latent TGF-BI  and TGF-E from fibroblast conditioned me- 
dinm can be activated by plasmin (Lyons et al., 1988, 1990). 
However,  in the  studies using fibroblast conditioned me- 
dium, only 30% of total acid activatable TGF-E could be ac- 
tivated by plasmin.  Recombinant El-LAP is  degraded by 
plasmin (Lyons et al., 1990), indicating that the small latent 
TGF-B1 complex might be the target for direct plasmin acti- 
vation. LTBP could mask plasmin sensitive bonds of LAP al- 
lowing more rigorous control for large latent TGF-E  acti- 
vation. 
Recombinant  El-LAP  contains  mannose  6-phosphate 
(Purchio et al., 1989; Kovacina et al., 1989), and the activa- 
tion of latent forms of TGF-E  in co-culture of endothelial 
cells and smooth muscle cells requires binding to the cation 
independent mannose 6-phosphate/IGF 1I receptor (Dennis 
and RiflOn, 1991). Mannose 6-phosphate is a lysosome spe- 
cific targeting signal (for review see Kornfeld, 1992), which 
should result in eventual transport of latent TGF-BI to the 
lysosomal compartment. Latent TGF-B1 is, however,  a se- 
creted protein. This apparent discrepancy can be resolved by 
the possibility that in the absence of LTBP latent TGF-/31 is 
retained in the cis aspect of the Golgi apparatus (Miyazono 
et al.,  1992),  while sorting of vesicles containing proteins 
targeted to the lysosomes occurs in the trans-Golgi network, 
later in the secretory pathway (see Rothman and Orci, 1992; 
Pryer et al., 1992; Kornfeld, 1992).  In addition, some pro- 
teins containing mannose-6-phosphate are secreted prior to 
transport to lysosomes (Chao et al., 1990; Kornfeld, 1992). 
LTBP could act as an override targeting signal, either by 
masking the mannose-6-phosphate of the small latent TGF-~ 
complex, or by blocking postsecretion transport by associa- 
tion to the ECM. Cleavage of LTBP by proteinases releasing 
latent TGF-E1 from the extracellular matrix could possibly 
result in "unmasking" of the mannose 6-phosphate and retar- 
geting of latent TGF-E1 to cell surface or to lysosomal com- 
partment for activation. 
A second possibility is also consistent with available data. 
It has been shown that cation independent mannose 6-phos- 
phate receptor participates in extracellular matrix degrada- 
tion by transferring lysosomal hydrolases to the cell surface 
(Brauker et al.,  1986;  see also Chao et al.,  1990).  Rather 
than acting directly, the inactivation of the mannose 6-phos- 
phate receptor by antibodies or competing ligand could thus 
inhibit TGF-E activation by restricting the supply ofmatrix- 
derived latent TGF-E. The importance of proper matrix as- 
sembly to TGF-E1 activation is also demonstrated in a study 
showing that inhibitors of a matrix cross-linking enzyme, 
transglutaminase, inhibit TGF-B1 activation in retinol treated 
endothelial cells (Kojima et al.,  1993). 
The  association  of  latent  "IGF-E  complexes  with  the 
pericellular matrices and their release by proteinases im- 
plies that these events participate in a number of biological 
events where enhanced or focal proteolysis takes place, in- 
cluding cell invasion, tissue remodeling and wound healing. 
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